-
公开(公告)号：EP2952510A4
公开(公告)日：2017-02-15
申请号：EP14746385
申请日：2014-01-27
申请人： CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD , CENTAURUS BIOPHARMA CO LTD , LIANYUNGANG RUNZHONG PHARMACEUTICAL CO LTD
发明人： XIAO DENGMING , XU XINHE , LIU XIJIE , HU YUANDONG , YU HONGHAO , LIU ZHIHUA , PENG YONG , SUN YINGHUI , LUO HONG , KONG FANSHENG , HAN YONGXIN , SUN JIAN
IPC分类号： C07D401/04 , A61K31/444 , A61K31/4545 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K31/675 , A61P35/00 , C07D213/73 , C07D213/74 , C07D401/06 , C07D401/14 , C07F9/6558
CPC分类号： C07D401/14 , A61K31/444 , A61K31/4545 , A61K31/506 , A61K31/5377 , A61K31/675 , C07D213/73 , C07D213/74 , C07D401/04 , C07D401/06 , C07F9/65583
摘要： Disclosed are a 2-aminopyridine derivative having protein kinase inhibition activity, a preparation method and a pharmaceutical composition thereof Also disclosed are uses of the compounds and the pharmaceutical compositions thereof in the preparation of drugs for treating and/or preventing protein kinase-related diseases.
摘要翻译： 公开了具有蛋白激酶抑制活性的2-氨基吡啶衍生物，其制备方法和药物组合物。还公开了化合物及其药物组合物在制备用于治疗和/或预防蛋白激酶相关疾病的药物中的用途。
-
公开(公告)号：EP3235819A4
公开(公告)日：2017-11-01
申请号：EP15869312
申请日：2015-12-15
申请人： CENTAURUS BIOPHARMA CO LTD , CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD , LIANYUNGANG RUNZHONG PHARMACEUTICAL CO LTD
发明人： ZHU LI , XIAO DENGMING , HU YUANDONG , DAI LIGUANG , DUAN XIAOWEI , SUN YINGHUI , PENG YONG , KONG FANSHENG , LUO HONG , HAN YONGXIN , YANG LING , WANG SHANCHUN
IPC分类号： C07D487/04 , A61K31/519 , A61K31/5377 , A61P35/00
CPC分类号： A61K31/519 , A61K31/5377 , C07D487/04
摘要： The present application relates to the field of pharmaceutical chemistry, and in particular, to a pyrrolopyrimidine compound represented by general formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. The present invention further relates to a method for preparing the pyrrolopyrimidine compound represented by general formula (I), pharmaceutical compositions and an application of the pyrrolopyrimidine compound in treating diseases mediated by Janus Kinase.
-
公开(公告)号：EP3050880A4
公开(公告)日：2017-04-26
申请号：EP14849754
申请日：2014-09-28
申请人： CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD , CENTAURUS BIOPHARMA CO LTD , LIANYUNGANG RUNZHONG PHARMACEUTICAL CO LTD
发明人： XIAO DENGMING , ZHU YAN , HU YUANDONG , WANG HUTING , LI JIJUN , PENG YONG , ZHANG HUI , LUO HONG , KONG FANSHENG , HAN YONGXIN
IPC分类号： C07D401/12 , A61K31/517 , A61K31/5377 , A61P35/00 , C07D401/14 , C07D403/12 , C07D405/14
CPC分类号： C07D403/12 , C07D401/12 , C07D401/14 , C07D405/14
摘要： The present invention relates to a quinazoline derivative shown in formula (I) and a preparation method therefor, a pharmaceutical composition comprising the compound shown in formula (I), and an application of the compound in preparing drugs for curing and preventing tumors. The compound of the present invention can irreversibly prevent EGFR phosphorylation, and effectively depress signal transduction of cancer cells, and accordingly has higher anti-tumor activity in vitro and in vivo.
摘要翻译： 本发明涉及式（I）所示的喹唑啉衍生物及其制备方法，含有式（I）所示化合物的药物组合物，以及该化合物在制备治疗和预防肿瘤药物中的应用。 本发明化合物可以不可逆地阻止EGFR的磷酸化，有效抑制癌细胞的信号传导，因此具有较高的体外和体内抗肿瘤活性。
-
公开(公告)号：EP2635587A4
公开(公告)日：2014-03-19
申请号：EP11837567
申请日：2011-11-01
发明人： XIAO DENGMING , ZHU LI , HU YUANDONG , WANG SHIXIN , YU RONG , HU WEI , LIANG ZHI , LIU XIJIE , HU QUAN
IPC分类号： C07D491/048 , A61K31/4355 , A61K31/4365 , A61K31/437 , A61K31/4545 , A61K31/5377 , A61P29/00 , A61P35/00 , C07D495/04 , C07D498/04 , C07D513/04
CPC分类号： C07D513/04 , A61K31/4355 , A61K31/4365 , A61K31/437 , A61K31/4545 , A61K31/5377 , C07D491/048 , C07D495/04 , C07D498/04
-
公开(公告)号：EP2670746A4
公开(公告)日：2014-07-30
申请号：EP12742266
申请日：2012-01-31
发明人： XIAO DENGMING , ZHU YAN , HU YUANDONG , WANG HUTING , LIU YULIANG , LI JIJUN , SUN DEGUANG , WANG ZHE , WEI YONGHENG , WANG ZANPING , TANG GUOJING , JING LUTAO
IPC分类号： C07D401/12 , A61K31/4523 , A61P3/00 , A61P3/04 , A61P3/06 , A61P3/10 , A61P43/00 , C07D401/14 , C07D451/14
CPC分类号： C07D401/04 , C07D401/12 , C07D401/14 , C07D413/14 , C07D451/14 , C07D471/04
-
6.发明公开NOVEL ARYLALKENE DERIVATIVES AND USE THEREOF AS SELECTIVE ESTROGEN RECEPTOR MODULATORS 审中-公开中华神经病学杂志（DEREN VERWENDUNG ALS SELEKTIVEÖSTROGENREZEPTORMODULATOREN）
公开(公告)号：EP2797889A4
公开(公告)日：2015-06-03
申请号：EP12863580
申请日：2012-12-28
发明人： XIAO DENGMING , ZHU LI , HU YUANDONG , YU RONG , HU WEI , ZHAO NA , PENG YONG , LUO HONG , HAN YONGXIN
IPC分类号： C07D213/61 , C07C217/20 , C07C255/54 , C07D207/08 , C07D207/12 , C07D213/38 , C07D213/64 , C07D213/65 , C07D213/70 , C07D213/74 , C07D231/56 , C07D235/06 , C07D239/34 , C07D263/56 , C07D285/14 , C07D295/096 , C07D307/79 , C07D307/82 , C07D333/16 , C07D333/28 , C07D401/12
CPC分类号： C07C217/18 , C07C215/48 , C07C217/20 , C07C255/54 , C07C2601/14 , C07D207/09 , C07D207/12 , C07D213/38 , C07D213/61 , C07D213/63 , C07D213/64 , C07D213/74 , C07D231/56 , C07D239/34 , C07D285/10 , C07D307/81 , C07D307/82 , C07D333/20 , C07D333/28 , C07D405/06 , C07D405/12
-
7.发明公开KINASE MODULATING COMPOUNDS, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF 审中-公开KINASEMODULIERENDE VERBINDUNGEN，ZUSAMMENSETZUNGEN DAMIT UND IHRE VERWENDUNG
公开(公告)号：EP2780341A4
公开(公告)日：2015-06-03
申请号：EP12849393
申请日：2012-11-14
发明人： XIAO DENGMING , LI JIJUN , ZHU YAN , HU YUANDONG , WANG HUTING , WANG ZHE , WANG ZANPING , WEI YONGHENG , SUN YINGHUI , WU QIONG , ZHANG HUI , PENG YONG , KONG FANSHENG , SUN YING , LUO HONG , HAN YONGXIN
IPC分类号： C07D473/00 , A61K31/519 , A61K31/52 , A61P25/00 , A61P29/00 , A61P35/00 , A61P37/00 , C07D487/04
CPC分类号： C07D473/00 , C07D487/04
摘要： The invention provides a compound represented by formula (I) which may modulate a kinase, and a pharmaceutical composition thereof, as well as the method for preventing or treating a protein kinase mediated disease or condition.
摘要翻译： 本发明提供了可以调节激酶的式（I）表示的化合物及其药物组合物，以及用于预防或治疗蛋白激酶介导的疾病或病症的方法。
-
8.发明公开2,4-DIAMINO-6,7-DIHYDRO-5H-PYRROLO[2,3]PYRIMIDINE DERIVATIVES AS FAK/Pyk2 INHIBITORS 审中-公开2,4-二氨基-6,7-二氢-5H-吡咯并[2,3-b]嘧啶衍生物ALS FAK / PYK2-HEMMER
公开(公告)号：EP2661437A4
公开(公告)日：2014-07-02
申请号：EP12732345
申请日：2012-01-07
发明人： XIAO DENGMING , CHENG LIANG , LIU XIJIE , HU YUANDONG , XU XINHE , LIU ZHIHUA , ZHANG LIPENG , WU WEI , WANG SHULONG , SHEN YU , LI GEN , WANG YIN , ZHAO SHENG , LI CHONGLONG , TANG JIA , YU HONGHAO
IPC分类号： C07D487/04 , A61K31/505 , A61P29/00 , A61P31/00 , A61P35/00 , A61P37/02
CPC分类号： C07D487/04 , A61K31/4523 , A61K31/519 , A61K31/5377 , A61K31/541 , C07D401/12 , C07D413/12 , C07D417/12 , C07D493/12
摘要： The invention relates to a novel class of 2,4-diamino-6,7-dihydro-5H-pyrrolo[2,3]pyrimidine derivatives as a FAK and/or Pyk2 inhibitor, to a process for their preparation, and to a composition thereof, as well as to use of the compounds for the inhibiting FAK and/or Pyk2 and method for the treatment of a FAK and/or Pyk2 mediated disorder or disease.
摘要翻译： 本发明涉及一种新型的作为FAK和/或Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物，其制备方法和组合物 以及该化合物用于抑制FAK和/或Pyk2的方法和用于治疗FAK和/或Pyk2介导的病症或疾病的方法。
-
公开(公告)号：EP2925740A4
公开(公告)日：2016-06-08
申请号：EP13858966
申请日：2013-11-29
发明人： HAN YONGXIN , YU RONG , WANG ZANPING , LIANG ZHI , HU QUAN , ZHU LI , HU YUANDONG , SUN YINGHUI , ZHAO NA , PENG YONG , ZHAI XIAOFENG , LUO HONG , XIAO DENGMING
IPC分类号： C07D401/04 , A61K31/415 , A61K31/4155 , A61K31/454 , A61K31/496 , A61K31/5377 , A61P11/06 , A61P19/02 , A61P19/04 , A61P29/00 , A61P35/00 , A61P35/02 , A61P37/02 , C07D231/38 , C07D403/04
CPC分类号： C07D403/04 , C07D231/38 , C07D401/04
摘要： The invention provides novel poly-substituted 5-membered heterocyclic compounds represented by Formula (IV), or a pharmaceutically acceptable salt, solvate, metabolites, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided can be used as selective irreversible bruton's tyrosine kinase (Btk) inhibitors and is further useful to treat inflammatory, auto immune diseases associated with aberrant B-cell proliferation such as RA (rheumatoid arthritis) and cancers. This invention also provided the preparation of a medicament using of Formula (IV), and methods of preventing or treating diseases associated with excessive Btk activity in mammals, especially humans. Formula (IV)
摘要翻译： 本发明提供由式（IV）表示的新型多取代五元杂环化合物或其药学上可接受的盐，溶剂合物，代谢物，多晶型物，酯，互变异构体或前药，以及包含这些化合物的组合物。 所提供的化合物可用作选择性不可逆的布鲁特酪氨酸激酶（Btk）抑制剂，并且还可用于治疗与异常B细胞增殖（例如RA（类风湿性关节炎）和癌症）相关的炎性，自身免疫疾病。 本发明还提供了使用式（IV）的药物的制备，以及用于预防或治疗与哺乳动物尤其是人类中过量Btk活性相关的疾病的方法。 式（IV）
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.014 秒)
